Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Comparing biomarkers as principal surrogate endpoints.

Huang Y, Gilbert PB.

Biometrics. 2011 Dec;67(4):1442-51. doi: 10.1111/j.1541-0420.2011.01603.x. Epub 2011 Apr 22.

2.

Evaluating candidate principal surrogate endpoints.

Gilbert PB, Hudgens MG.

Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.

3.

Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints.

Gabriel EE, Sachs MC, Gilbert PB.

Stat Med. 2015 Feb 10;34(3):381-95. doi: 10.1002/sim.6349. Epub 2014 Oct 28.

4.

A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials.

Li Y, Taylor JM, Little RJ.

Biometrics. 2011 Dec;67(4):1434-41. doi: 10.1111/j.1541-0420.2011.01608.x. Epub 2011 May 31.

5.

Design and estimation for evaluating principal surrogate markers in vaccine trials.

Huang Y, Gilbert PB, Wolfson J.

Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.

7.

Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time.

Baker SG, Sargent DJ, Buyse M, Burzykowski T.

Biometrics. 2012 Mar;68(1):248-57. doi: 10.1111/j.1541-0420.2011.01646.x. Epub 2011 Aug 13.

8.

Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.

Gabriel EE, Gilbert PB.

Biostatistics. 2014 Apr;15(2):251-65. doi: 10.1093/biostatistics/kxt055. Epub 2013 Dec 13.

9.

Chop-lump tests for vaccine trials.

Follmann D, Fay MP, Proschan M.

Biometrics. 2009 Sep;65(3):885-93. doi: 10.1111/j.1541-0420.2008.01131.x. Epub 2009 Feb 5.

PMID:
19210727
10.

Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

Conlon AS, Taylor JM, Elliott MR.

Biostatistics. 2014 Apr;15(2):266-83. doi: 10.1093/biostatistics/kxt051. Epub 2013 Nov 26.

11.
12.

Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Baker SG, Kramer BS.

Clin Trials. 2015 Aug;12(4):299-308. doi: 10.1177/1740774514557725. Epub 2014 Nov 10.

13.

Bayesian adaptive trial design for a newly validated surrogate endpoint.

Renfro LA, Carlin BP, Sargent DJ.

Biometrics. 2012 Mar;68(1):258-67. doi: 10.1111/j.1541-0420.2011.01647.x. Epub 2011 Aug 12.

14.

Evaluating marker-guided treatment selection strategies.

Matsouaka RA, Li J, Cai T.

Biometrics. 2014 Sep;70(3):489-99. doi: 10.1111/biom.12179. Epub 2014 Apr 29.

15.

Statistical considerations for the next generation of clinical trials.

Wu W, Shi Q, Sargent DJ.

Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014. Review.

PMID:
21810519
16.

Identifying optimal biomarker combinations for treatment selection via a robust kernel method.

Huang Y, Fong Y.

Biometrics. 2014 Dec;70(4):891-901. doi: 10.1111/biom.12204. Epub 2014 Aug 14.

17.

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.

Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, Phillips A, Chêne G, Babiker A, Thiébaut R; NEAT-WP4..

Clin Trials. 2010 Feb;7(1):19-35. doi: 10.1177/1740774509356117. Review.

PMID:
20156955
18.

Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Weir CJ, Walley RJ.

Stat Med. 2006 Jan 30;25(2):183-203. Review.

PMID:
16252272
19.

Accommodating missingness when assessing surrogacy via principal stratification.

Elliott MR, Li Y, Taylor JM.

Clin Trials. 2013;10(3):363-77. doi: 10.1177/1740774513479522. Epub 2013 Apr 3.

20.

Surrogate endpoints in randomized cardiovascular clinical trials.

Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F.

Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Review.

PMID:
20698890

Supplemental Content

Support Center